Susan E. Atkins - 12 Aug 2026 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Reporting relationship: Director
Issuer ticker: BTAI
Reported as of: 12 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2026, 19:00:43 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Javier Rodriguez, Attorney-in-Fact for Susan E. Atkins

Key filing fact

Susan E. Atkins filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 14 Aug 2026.

Key facts

This page summarizes Susan E. Atkins's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Aug 2026, 19:00.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002111494 Primary reporting owner

Atkins Susan E.

Relationship: Director
Address: C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN
Signature: /s/ Javier Rodriguez, Attorney-in-Fact for Susan E. Atkins
Signature date: 14 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BTAI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +17,000
Change %
Price: $0.000000^*
Shares after: 17,000
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price: $1.06
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable as to 33% of the underlying shares on the first anniversary of the grant date, and the remaining shares vest in two equal annual installments thereafter on the second and third anniversary of the grant date, subject to the Reporting Person's continuous service with the Issuer through the relevant vesting dates.